{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000134","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.719420+00:00","generated_at":"2026-06-11T02:24:41.707898+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BeiGene reports H1 2023 R&D expenses of $831M; breakdown by key pipeline assets","bullets":["Total R&D expenses for H1 2023 were $831.3M, up from $768.1M in H1 2022.","Zanubrutinib R&D: $81.1M (H1 2023) vs $71.0M (H1 2022).","Tislelizumab R&D: $47.0M; Ociperlimab: $38.8M; Pamiparib: $4.4M.","Bcl-2 (BGB-11417) R&D: $17.5M; OX40 (BGB-A445): $8.9M; other projects: $60.6M.","Differences between PRC GAAP and US GAAP summarized, mainly share-based comp and leasing treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000134","json":"https://secwatch.observer/filing/0001651308-23-000134.json","markdown":"https://secwatch.observer/filing/0001651308-23-000134.md","text":"https://secwatch.observer/filing/0001651308-23-000134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000134/0001651308-23-000134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000134/bgne-20230829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:24:41.707898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}